The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Response-adapted treatment in CLL
Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, highlights the need for find the optimal duration of treatment in patients with chronic lymphocytic leukemia (CLL). Personalized treatments with durations based on patient needs, existing comorbidities, or disease factors can change how quickly patients can respond to treatment. Minimal residual disease (MRD) testing is therefore, important for personalized medicine by assessing when individual patients should cease treatment. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
